These findings were validated through tissue microarray (TMA) analysis and multicolor immunofluorescence staining of 198 liver cancer patient samples, confirming higher CD8+ T cell proportions in HBV+ samples compared to HCV+ and NBNC samples (Figure 1E,F; Figure S2B,C, Supporting Information). The gene discussed is CD8A; the disease is liver cancer.